

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6167151

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
DALIN TANG	02/12/2015
RECEIVING PARTY DATA	
Name:	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
Street Address:	980 GREAT WEST ROAD
Internal Address:	BRENTFORD
City:	MIDDLESEX
State/Country:	ENGLAND
Postal Code:	TW8 9GS
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16792346
CORRESPONDENCE DATA	
Fax Number:	(610)917-6934
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	215-932-8796
Email:	us_cipkop@gsk.com
Correspondent Name:	GLAXOSMITHKLINE
Address Line 1:	1250 SOUTH COLLEGEVILLE ROAD
Address Line 2:	UP4110
Address Line 4:	COLLEGEVILLE, PENNSYLVANIA 19426
ATTORNEY DOCKET NUMBER:	PR65637C2
NAME OF SUBMITTER:	WAYNE J. DUSTMAN
SIGNATURE:	/Wayne J. Dustman/
DATE SIGNED:	06/23/2020
Total Attachments: 3	
source=PR65637_Assignment_TANG#page1.tif	
source=PR65637_Assignment_TANG#page2.tif	
source=PR65637_Assignment_TANG#page3.tif	

Assignment

WHEREAS, I, **Dalin TANG**, a citizen of the People's Republic of China, residing at Shanghai, China, have invented or discovered certain improvements in **CRYSTALLINE FORMS** hereinafter referred to as said invention and improvements for which a priority application 61/929814 was filed on 21 Jan 2014 in the United States Patent Office, and for which a PCT international application PCT/IB2015/050440 was filed on 20 Jan 2015, designating the United States of America.

WHEREAS, the invention, being made in the course of my employment, belongs to my employer at that time, namely **SHANGHAI STA PHARMACEUTICAL R&D CO., LTD.**, a company duly organized and existing under the law of China, and having its principal business address Building 7, No 90 Delin Road, Waigaoqiao Free Trade Zone, Shanghai, 200131, P.R. China, and whereas **SHANGHAI STA PHARMACEUTICAL R&D CO., LTD.** is an affiliate of **STA PHARMACEUTICAL HONG KONG LTD.**, which is a company duly organized and existing under the law of China, and having its principal business address at 304 Dominion CRT, 43 Queen's Rd East, Wanchai, Hong Kong P.R. China, and whereas both **SHANGHAI STA PHARMACEUTICAL R&D CO., LTD.** and **STA PHARMACEUTICAL HONG KONG LTD.** are wholly owned subsidiaries of **SHANGHAI SYNTHETICAL PHARMACEUTICAL CO., LTD.**, a company duly organized and existing under the law of China, and having its offices at No. 9 Yuegong Road (west) Shanghai Chemical Park, Shanghai, China.

WHEREAS, **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED**, registered in England and Wales under company number 835139 and having its registered office at 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom, has acquired the whole right, title and interest in and to said invention and improvements and said application, and in and to any Letters Patent to be obtained therefor, in the United States, its territories and possessions, and in and to any applications for said invention and improvements and any Letters Patent to be obtained therefor, in all countries other than the United States, its territories and possessions by virtue of a Fee for Service Framework Agreement for Compound Development, Drug Development and Manufacture of non-GMP and cGMP API and/or Bulk Drug Product between **STA PHARMACEUTICAL HONG KONG LIMITED** and **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** which went into effect on 23 December 2011.

WHEREAS **GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED**, a corporation organized and existing under and by virtue of the laws of England and having its trading office

PR65637
Docket Number

address at 980 Great West Road, Brentford, Middlesex TW8 9GS, England, is desirous of acquiring the whole right, title and interest in and to the invention and in and to any applications for the invention and any Letters Patent to be obtained therefor in all countries, including the United States of America, its territories and possessions.

NOW, THEREFORE, to all whom it may concern, be it known that I, Dalin TANG, hereby confirm the ownership by SHANGHAI STA PHARMACEUTICAL R&D CO., LTD. of the invention and the application by operation of law and, if under the law of United States or any other countries, I the inventor have any ownership right, title and interest in and to the invention and the application, (which I do not believe to be the case and claim no ownership right, title or interest in and to the invention and to the application based on the law of United States or any other countries), I the inventor nevertheless hereby assign and transfer such ownership right, title and interest in and to the invention and to the application, including the right to claim priority from the application in respect of any subsequent applications, to SHANGHAI STA PHARMACEUTICAL R&D CO., LTD.,

SHANGHAI STA PHARMACEUTICAL R&D CO., LTD., in turn hereby assigns and transfers to GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED, its whole right title and interest in all countries, including the United States of America, its territories and possessions in and to the invention and in and to the application including the right to claim priority from the application in respect of any subsequent applications, and in and to any divisional application, continuation or continuation in part application thereof, and in and to any Supplementary Protection Certificate, extension or re-issue thereof, and I the inventor and SHANGHAI STA PHARMACEUTICAL R&D CO., LTD., hereby authorize and request any patent arising therefrom, in all countries, including the United States of America, its territories and possessions, be issued to GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED.

GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED in turn hereby assigns and transfers to GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED its whole right, title and interest in all countries, including the United States of America, its territories and possessions in and to the invention and in and to the application including the right to claim priority from the application in respect of any subsequent applications, and in and to any divisional application, continuation or continuation in part application thereof, and in and to any Supplementary Protection Certificate, extension or re-issue thereof, and I the inventor and SHANGHAI STA PHARMACEUTICAL R&D CO., LTD., and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED hereby authorize and request any patent arising therefrom,

PATENT
REEL: 035074 FRAME: 0064


PATENT
REEL: 053014 FRAME: 0479


in all countries, including the United States of America, its territories and possessions, be issued to
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED,


And SHANGHAI STA PHARMACEUTICAL R&D CO., LTD., GLAXOSMITHKLINE
RESEARCH AND DEVELOPMENT LIMITED hereby, and I the inventor for myself and my respective
executors and legal representatives hereby, agree at the request and cost of GLAXOSMITHKLINE
INTELLECTUAL PROPERTY (NO.2) LIMITED to provide information and make execute and deliver any
and all other instruments, in writing and any and all further acts, applications, papers, affidavits, assignments
and other documents which may be possible and are necessary or desirable to more effectually secure to and
vest in GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED its successors and
assigns, the whole right, title and interest in and to the invention and in and to the application hereby assigned
and transferred in all countries, including the United States of America, its territories and possessions.

IN WITNESS WHEREOF, I have hereunto set my hand and affixed my seal on the date(s) indicated

below


Dafin TANG _____ Date 02/12/2015


Name Xiaoyang Fu _____ Date Feb. 13, 2015
Authorized Official, SHANGHAI STA PHARMACEUTICAL R&D CO., LTD. SEA
PHARMACEUTICAL HONG KONG LTD, and SHANGHAI SYNTHETICAL PHARMACEUTICAL
CO., LTD.


John L. Lemaniowicz _____ Date 19 Feb 2015
Authorized Official, GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED and
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED